Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company focused on neurodegenerative disorder treatments, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company met Nasdaq's Rule 5550(a)(2) by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive business days, achieving this milestone on August 25, 2025.

Following this achievement, Nasdaq has officially closed the bid price deficiency matter, confirming Cognition's continued listing on the exchange.

Positive

• Successfully regained Nasdaq compliance, removing delisting risk
• Maintained share price above $1.00 for required period
• Continues to maintain Nasdaq listing status

Negative

• Previous trading below $1.00 minimum bid price requirement indicates recent stock price weakness

PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was notified by The Nasdaq Listing Qualifications Staff (“Nasdaq”) that the Company has regained compliance with the exchange’s continued listing standard for minimum share price under Rule 5550(a)(2) (the “Bid Price Rule”).

To regain compliance with the Bid Price Rule, the Company's shares of common stock were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on August 25, 2025. Accordingly, Nasdaq informed the Company that it considers the bid price deficiency matter now closed.

About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We recently completed Phase 2 studies of our lead candidate, zervimesine (CT1812) in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry AMD. The Phase 2 START study (NCT05531656) in early Alzheimer’s disease is ongoing with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.

Contact Information: Cognition Therapeutics, Inc. info@cogrx.com	Mike Moyer (investors)  LifeSci Advisors  mmoyer@lifesciadvisors.com

This press release was published by a CLEAR® Verified individual.

FAQ

Has Cognition Therapeutics (CGTX) regained Nasdaq compliance in 2025?

Yes, Cognition Therapeutics regained compliance with Nasdaq's minimum bid price requirement on August 25, 2025 by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive business days.

What is Nasdaq's minimum bid price requirement that CGTX had to meet?

According to Nasdaq Rule 5550(a)(2), companies must maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days to maintain listing compliance.

What happens now that CGTX has regained Nasdaq compliance?

Nasdaq has informed Cognition Therapeutics that the bid price deficiency matter is now closed, and the company will continue its listing on the Nasdaq exchange.

What type of company is Cognition Therapeutics (CGTX)?

Cognition Therapeutics is a clinical-stage company that develops drugs for treating neurodegenerative disorders.